Mandate

Vinge advises Komatsu Forest on acquisition of Log Max

October 23, 2012

Vinge is advising Komatsu Forest AB in connection with the acquisition of Log Max AB and Log Max AB’s US subsidiary Log Max Inc. Komatsu Forest AB is a wholly-owned subsidiary to Komatsu Ltd., who manufactures and sells construction and mining equipment, utilities, forest machines and industrial machinery, with a turnover of approx. USD 21bn. and approx. 44,000 employees, and who is listed inter alia on the Tokyo stock exchange. Log Max, with head office in Grangärde, manufactures and sells equipment for mechanized forestry operations and in particular grapple harvesters - a device that will grip and fell a tree, and cut it to desired lengths.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

The Vinge team included partners Carl Gustaf De Geer and Malin Ohlin, and associates Nina Farrahi and Peter Sundgren (M&A), associates Christian Hybinette and Eric Ödling (commercial agreements), partner Marcus Glader and associate Peter Alstergren (EU and competition law), associate Johan Cederblad (environmental law), associate Claes Henriksson (IP law), and associate Emma Lindelöf (employment law).

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024